IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals has submitted copies of its audited financial results for Q4 FY25 and the full year ended 31st March 2025, as published in Financial Express, Economic Times, Business Standard and Punjabi Jagran on 17th May 2025. On a standalone basis, total income for FY25 stood at ₹2,101.61 crore, slightly lower than ₹2,162.86 crore in FY24. Net profit after tax for FY25 was ₹101.00 crore versus ₹135.42 crore in the previous year, a decline of about 25%. Q4 FY25 however showed improvement, with net profit rising to ₹31.62 crore from ₹28.19 crore in Q4 FY24, and total income at ₹532.30 crore. Basic and diluted EPS for the full year was ₹3.44 versus ₹4.61 in FY24. Consolidated figures were broadly similar to standalone numbers.
While quarterly performance improved year-on-year, the full-year results show a meaningful drop in profit despite stable revenue, which may weigh on near-term investor sentiment. The filing itself is a routine regulatory disclosure of already-published results, so no new market-moving action is expected from this submission alone.